Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ARVN NASDAQ:PRQR NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.86-1.9%$3.90$1.16▼$5.12$679.45M0.762.05 million shs183,660 shsARVNArvinas$9.49-1.8%$11.29$5.90▼$14.51$614.55M1.79843,861 shs692,673 shsPRQRProQR Therapeutics$1.59-1.6%$1.69$1.33▼$3.10$167.10M0.08522,496 shs131,195 shsSLDBSolid Biosciences$7.44-3.1%$7.45$2.41▼$8.87$732.76M2.471.23 million shs138,522 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+0.41%+12.24%+22.52%+35.62%+292.86%ARVNArvinas-4.45%-8.09%-10.72%-28.13%+46.14%PRQRProQR Therapeutics+1.90%+3.87%-12.97%+8.78%0.00%SLDBSolid Biosciences+5.64%+7.71%-4.24%+10.82%+177.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.86-1.9%$3.90$1.16▼$5.12$679.45M0.762.05 million shs183,660 shsARVNArvinas$9.49-1.8%$11.29$5.90▼$14.51$614.55M1.79843,861 shs692,673 shsPRQRProQR Therapeutics$1.59-1.6%$1.69$1.33▼$3.10$167.10M0.08522,496 shs131,195 shsSLDBSolid Biosciences$7.44-3.1%$7.45$2.41▼$8.87$732.76M2.471.23 million shs138,522 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+0.41%+12.24%+22.52%+35.62%+292.86%ARVNArvinas-4.45%-8.09%-10.72%-28.13%+46.14%PRQRProQR Therapeutics+1.90%+3.87%-12.97%+8.78%0.00%SLDBSolid Biosciences+5.64%+7.71%-4.24%+10.82%+177.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.29132.46% UpsideARVNArvinas 2.40Hold$14.8656.57% UpsidePRQRProQR Therapeutics 2.63Moderate Buy$7.25357.41% UpsideSLDBSolid Biosciences 2.92Moderate Buy$16.09116.16% UpsideCurrent Analyst Ratings BreakdownLatest PRQR, SLDB, ARVN, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/27/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/27/2026SLDBSolid Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SLDBSolid Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.004/16/2026ACRSAclaris Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M86.60N/AN/A$0.85 per share5.71ARVNArvinas$262.60M2.33N/AN/A$6.76 per share1.40PRQRProQR Therapeutics$17.99M9.28N/AN/A$0.53 per share2.99SLDBSolid BiosciencesN/AN/AN/AN/A$2.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%N/AARVNArvinas-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/12/2026 (Estimated)PRQRProQR Therapeutics-$47.73M-$0.46N/AN/AN/A-255.83%-65.89%-31.53%5/12/2026 (Estimated)SLDBSolid Biosciences-$174.32M-$2.02N/AN/AN/AN/A-72.23%-59.27%5/21/2026 (Estimated)Latest PRQR, SLDB, ARVN, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026SLDBSolid Biosciences-$0.40N/AN/AN/AN/AN/A5/12/2026Q1 2026PRQRProQR Therapeutics-$0.15-$0.15N/A-$0.15$5.19 million$2.35 million5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million3/19/2026Q4 2025SLDBSolid Biosciences-$0.51-$0.50+$0.01-$0.53N/AN/A3/12/2026Q4 2025PRQRProQR Therapeutics-$0.08-$0.09-$0.01-$0.09$6.12 million$5.53 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 million2/24/2026Q4 2025ARVNArvinas-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03ARVNArvinasN/A4.924.92PRQRProQR TherapeuticsN/A3.093.09SLDBSolid BiosciencesN/A6.146.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ARVNArvinas95.19%PRQRProQR Therapeutics32.65%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%ARVNArvinas7.30%PRQRProQR Therapeutics8.40%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableARVNArvinas42064.52 million59.81 millionOptionablePRQRProQR Therapeutics180105.36 million96.51 millionOptionableSLDBSolid Biosciences10098.41 million85.00 millionOptionablePRQR, SLDB, ARVN, and ACRS HeadlinesRecent News About These CompaniesSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 12 at 2:13 AM | americanbankingnews.comSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyMay 7, 2026 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyApril 30, 2026 | globenewswire.comSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyApril 28, 2026 | markets.businessinsider.comSolid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist FinancialApril 28, 2026 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street ZenApril 19, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)April 17, 2026 | theglobeandmail.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 17, 2026 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Sets New 12-Month High - Here's What HappenedApril 14, 2026 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - Here's WhyApril 13, 2026 | marketbeat.comSolid Biosciences Adjusts Board Classes in Governance MoveApril 12, 2026 | theglobeandmail.comSolid Biosciences to Participate at Upcoming Investor ConferencesApril 7, 2026 | globenewswire.comJ.P. Morgan Issues a Buy Rating on Solid Biosciences (SLDB)March 27, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Mereo Biopharma Group Plc (MREO)March 22, 2026 | theglobeandmail.comGuggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendationMarch 21, 2026 | msn.comSolid Bio wins new buy at Guggenheim on lead assetMarch 20, 2026 | msn.comSolid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 20, 2026 | finanznachrichten.deSolid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 19, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB)March 17, 2026 | theglobeandmail.comChardan Capital Issues a Buy Rating on Solid Biosciences (SLDB)March 13, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRQR, SLDB, ARVN, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.86 -0.10 (-1.92%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Arvinas NASDAQ:ARVN$9.49 -0.17 (-1.77%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.ProQR Therapeutics NASDAQ:PRQR$1.58 -0.03 (-1.55%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Solid Biosciences NASDAQ:SLDB$7.44 -0.24 (-3.07%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
